LATEST

• REGULATORY Japan Approves Zepbound, Qalsody, and Lots More Drugs
  December 27, 2024

• REGULATORY Quality Assurance and Lag/Loss Fight to Form Pillars of PMD Act Amendment
  December 27, 2024

• BUSINESS J&J Bags Kaken’s STAT6 Inhibitor, Set to Take 6% Stake in Japan Firm
  December 27, 2024

• BUSINESS Santen Files RVL Pharma’s Droopy Eyelid Drug in Japan
  December 27, 2024

• REGULATORY LDP Members Urge Ministers to End “Mechanical” Off-Year Price Cuts
  December 27, 2024

• ORGANIZATION Japan Generic Use Rate at 84.7% in July-September: JGA
  December 27, 2024

• REGULATORY Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
  December 26, 2024

• ORGANIZATION PhRMA/EFPIA Lash Out at Japan’s Plan for Mandatory Startup Fund
  December 26, 2024

• ORGANIZATION PhRMA/EFPIA Slam Govt for Off-Year Revision as Broader Industry Deplores Decision
  December 26, 2024

• REGULATORY Gist of FY2025 Drug Price Revision
  December 26, 2024

• REGULATORY Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
  December 26, 2024

• BUSINESS Meiji Pharma Sues CDP Lawmaker for Defamation over Kostaive
  December 26, 2024

• REGULATORY DPP’s Tamaki Rails Against Govt’s Price Revision Decision
  December 26, 2024

• BUSINESS ASKA In-Licenses Another Women’s Health Drug from Insud
  December 26, 2024

• BUSINESS Sandoz’s Rituximab Biosimilar Adds Pediatric ITP Indication
  December 26, 2024

• REGULATORY Japan Doles Out Orphan Tags for Nihon Servier’s Vorasidenib, 11 More APIs
  December 26, 2024

• REGULATORY Maruishi’s Midazolam Designated as Drug for Specific Use
  December 26, 2024

• TRENDS Top 10 PHARMA JAPAN Articles of 2024
  December 25, 2024

• BUSINESS Nihon Servier Files Glioma Drug Vorasidenib in Japan
  December 25, 2024

• BUSINESS Sumitomo’s Gemtesa Expands Label in US to OAB Patients with BPH
  December 25, 2024

ページ

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »